Short Interest in CalciMedica Inc. (NASDAQ:CALC) Rises By 497.8%

CalciMedica Inc. (NASDAQ:CALC) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 1,651,945 shares, an increase of 497.8% from the June 15th total of 276,326 shares. Approximately 17.9% of the shares of the company are short sold. Based on an average trading volume of 6,188,729 shares, the days-to-cover ratio is currently 0.3 days.

CalciMedica Stock Performance

Shares of CALC stock traded down $0.02 on Friday, reaching $0.93. 178,067 shares of the company were exchanged, compared to its average volume of 3,401,162. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20. The business has a 50-day moving average price of $0.79 and a 200 day moving average price of $1.67. The company has a market cap of $14.69 million, a price-to-earnings ratio of -0.71 and a beta of 0.89.

Insider Transactions at CalciMedica

In related news, Director Fred A. Middleton purchased 248,972 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was bought at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the acquisition, the director owned 1,063,272 shares of the company’s stock, valued at $850,617.60. The trade was a 30.57% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 41.55% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

A number of hedge funds have recently made changes to their positions in CALC. Renaissance Technologies LLC lifted its position in shares of CalciMedica by 45.0% in the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after acquiring an additional 39,775 shares in the last quarter. 180 Wealth Advisors LLC increased its position in shares of CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in CalciMedica in the 4th quarter valued at $506,000. Finally, PVG Asset Management Corp purchased a new position in CalciMedica in the 4th quarter valued at $302,000.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CalciMedica in a research note on Tuesday. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.